COCP: Presentation Highlights CDI-988
On May 15, 2026, Cocrystal Pharma, Inc. (COCP) announced financial results for the first quarter of 2026 ending March 31, 2026 and provided a...
53 Views
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention
On March 31, 2026, Cocrystal Pharma, Inc. (COCP) announced financial results for the year ending December 31, 2025 and provided a business...
115 Views
COCP: CDI-988 Data to be Presented at ICAR 2026
On February 19, 2026, Cocrystal Pharma, Inc. (COCP) announced that initial data from the Phase 1b norovirus challenge study of CDI-988 will be...
268 Views
COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26
On November 14, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for the third quarter of 2025 and provided a business update. The...
226 Views
COCP: CDI-988 Showcased at Calicivirus Conference Direct Offering Raises Up to 13 Million
On September 12, 2025, Cocrystal Pharma, Inc. (COCP) announced a presentation on CDI-988 at the 9th International Calicivirus Conference. The...
271 Views